- Home
- TIL vs BCAB Comparison
TIL vs BCAB Comparison
Compare TIL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- BCAB
- Stock Information
- Founded
- TIL 2018
- BCAB 2007
- Country
- TIL United States
- BCAB United States
- Employees
- TIL N/A
- BCAB N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- TIL Health Care
- BCAB Health Care
- Exchange
- TIL Nasdaq
- BCAB Nasdaq
- Market Cap
- TIL 230.1M
- BCAB 22.3M
- IPO Year
- TIL 2021
- BCAB 2020
- Fundamental
- Price
- TIL $23.81
- BCAB $0.40
- Analyst Decision
- TIL Buy
- BCAB Buy
- Analyst Count
- TIL 5
- BCAB 2
- Target Price
- TIL $119.00
- BCAB $1.00
- AVG Volume (30 Days)
- TIL 334.3K
- BCAB 523.2K
- Earning Date
- TIL 08-12-2025
- BCAB 08-07-2025
- Dividend Yield
- TIL N/A
- BCAB N/A
- EPS Growth
- TIL N/A
- BCAB N/A
- EPS
- TIL N/A
- BCAB N/A
- Revenue
- TIL N/A
- BCAB $11,000,000.00
- Revenue This Year
- TIL N/A
- BCAB N/A
- Revenue Next Year
- TIL N/A
- BCAB N/A
- P/E Ratio
- TIL N/A
- BCAB N/A
- Revenue Growth
- TIL N/A
- BCAB N/A
- 52 Week Low
- TIL $9.62
- BCAB $0.24
- 52 Week High
- TIL $92.00
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- TIL 45.83
- BCAB 46.46
- Support Level
- TIL $20.60
- BCAB $0.36
- Resistance Level
- TIL $31.67
- BCAB $0.43
- Average True Range (ATR)
- TIL 3.53
- BCAB 0.04
- MACD
- TIL -1.54
- BCAB -0.00
- Stochastic Oscillator
- TIL 17.93
- BCAB 30.65
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.